Tag: EUA
-
State of Legal Contests Over mRNA and Other Vaccine Mandates (as of January 2026)
by James Lyons-Weiler, PhD, Popular Rationalism, ©2026 (Jan. 16, 2026) — This article provides a comprehensive, plain‑language yet legally rigorous account of the current state of legal contests surrounding mRNA COVID‑19 vaccine mandates in the United States as of January 2026. It focuses primarily on students and healthcare workers, the two groups most frequently subjected to compulsory vaccination as…
-
BREAKING: FDA Rescinds Emergency Use Authorization for COVID-19 Vaccines
by James Lyons-Weiler, PhD, Popular Rationalism, ©2025 (Aug. 27, 2025) — The U.S. Food and Drug Administration (FDA) has rescinded the emergency use authorizations (EUAs) for COVID-19 vaccines, narrowing their availability to high-risk groups. Health and Human Services Secretary Robert F. Kennedy Jr. announced the change on Wednesday, describing it as a step to end…
-
FDA Rubber Stamps Experimental NOVAVAX 2024-2025 COVID-19 Vaccine with Zero Clinical Data
by James Lyons-Weiler, PhD, Popular Rationalism, ©2024 (Aug. 31, 2024) — The U.S. Food and Drug Administration (FDA) recently authorized an updated version of the Novavax COVID-19 vaccine under Emergency Use Authorization (EUA). This decision has raised significant concerns due to the absence of new clinical trial data supporting the updated vaccine’s safety and efficacy.…
-
On the 99M Person Study Allegedly Showing Rare Neurologic, Cardiac, and Hematologic Conditions Following COVID-19 Vaccination
by James Lyons-Weiler, Popular Rationalism, ©2024 (Feb. 22, 2024) — Let’s get right to the facts about the most recent study. Some important facts about this study: A. ARBITRARY SIGNIFICANCE LEVEL Without justification, the authors adopted a lower bound confidence interval of LBCI > 1.5+0.95CI as a significance level cut-off for prioritized safety signals. LCBI…
-
CDC’s and FDA’s Latest COVID-19 Vaccine Guidance
by Dvorah Richman, ©2023 (May 5, 2023) — Most people are confused about COVID-19 vaccines, and many don’t trust what they hear. COVID-19 fatigue is rampant, and the response to mRNA bivalent COVID-19 vaccines has been tepid. Into this fraught environment comes the Food and Drug’s April 19 announcement (and after that an announcement one…
-
CDC’s 4 Step Scheme That Destroyed Medical Credibility
by John Anthony, Sustainable Freedom Lab, ©2022 (Aug. 1, 2022) — Still think it is inconceivable so many trusted hospitals and medical professionals would inflate COVID hospitalizations and deaths making the pandemic appear worse than it was? Consider this. In February of 2020, the CDC released projections of COVID’s spread largely based on the flawed Imperial…
-
The CDC Is Sacrificing Kids for Big Pharma
by Dr. Joseph Mercola, ©2022 (Jul. 26, 2022) — “Why the Rush for Toddler Vaccines?” asks Wall Street Journal editorial board member Allysia Finley in a July 4, 2022, op-ed.1 Indeed, many are asking that same question, and I’m glad the legacy media’s WSJ had the courage to print it. In the last days of…
-
Why the FDA’s Delay of Pfizer’s EUA for Children is Catastrophic for Vaccines
by John Anthony, Sustainable Freedom Lab, ©2022 (Feb. 12, 2022) — On Feb 11, the FDA made the shocking announcement they are postponing the Advisory Committee meeting to approve the EUA for Pfizer’s vaccines for children 6 months to 4 years of age. The press dutifully repeated the official release explaining that more testing is…
-
Twitter Suspends Account of “The Obama Timeline” Author
by Sharon Rondeau (Dec. 6, 2021) — On Sunday, the author of the long-running “The Obama Timeline” website, Don Fredrick, reported his Twitter account suspended permanently for allegedly “violating the Twitter rules.” The suspension was invoked for “violating our policy on spreading misleading and potentially harmful information related to COVID-19,” Twitter wrote on its notice.…
-
Why Can’t the FDA Answer These Simple Questions?
by Sharon Rondeau (Oct. 2, 2021) — Questions The Post & Email posed more than a week ago to the FDA regarding COVID-19 vaccines remain unanswered despite person-to-person contact between this writer and an FDA representative. On Wednesday, September 22, The Post & Email contacted the FDA’s Center for Biologics Evaluation and Research (CBER) by…